Compugen Ownership
| CGEN Stock | USD 1.65 0.02 1.20% |
Shares in Circulation | First Issued 2000-03-31 | Previous Quarter 93.5 M | Current Value 93.5 M | Avarage Shares Outstanding 47.5 M | Quarterly Volatility 23.8 M |
Compugen Stock Ownership Analysis
About 14.0% of the company shares are held by institutions such as insurance companies. The book value of Compugen was currently reported as 0.47. The company recorded a loss per share of 0.3. Compugen had not issued any dividends in recent years. Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Compugen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people. For more info on Compugen please contact Anat CohenDayag at 972 3 765 8585 or go to https://cgen.com.Besides selling stocks to institutional investors, Compugen also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Compugen's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Compugen's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Compugen Quarterly Liabilities And Stockholders Equity |
|
Roughly 2.0% of Compugen are currently held by insiders. Unlike Compugen's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Compugen's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Compugen's insider trades
Compugen Outstanding Bonds
Compugen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Compugen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Compugen bonds can be classified according to their maturity, which is the date when Compugen has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Pair Trading with Compugen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compugen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will appreciate offsetting losses from the drop in the long position's value.Moving together with Compugen Stock
Moving against Compugen Stock
| 0.55 | HBIO | Harvard Bioscience | PairCorr |
| 0.43 | OSL | Oncosil Medical | PairCorr |
| 0.38 | GSS | Genetic Signatures | PairCorr |
| 0.34 | CDT | Conduit Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Compugen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compugen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compugen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compugen to buy it.
The correlation of Compugen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compugen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compugen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compugen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Will Life Sciences Tools & Services sector continue expanding? Could Compugen diversify its offerings? Factors like these will boost the valuation of Compugen. Projected growth potential of Compugen fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Compugen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.30) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
Investors evaluate Compugen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Compugen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Compugen's market price to deviate significantly from intrinsic value.
It's important to distinguish between Compugen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Compugen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Compugen's market price signifies the transaction level at which participants voluntarily complete trades.